A Feasibility And Toxicity Study Of Vaccination With HSP70 For The Treatment Of Chronic Myelogenous Leukemia In Chronic Phase

NCT00030303 Phase 1 COMPLETED

RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.

Details

Lead sponsor	UConn Health
Phase	Phase 1
Status	COMPLETED
Enrolment	20
Start date	2001-01
Completion	2004-01

Conditions

• Leukemia

Interventions

• recombinant 70-kD heat-shock protein

Countries

United States